The endpoints analyzed to time were change from baseline vs placebo at 24 weeks in TDI and in SGRQ of a one stage switch in TDI in both studies, and a four stage switch in SGRQ in the AUGMENT/COPD study. Additional analyses, including those on pooled data, will become presented at long term scientific meetings. Additionally, both aclidinium/formoterol treatment arms were well-tolerated in this research.1 percent, 3.9 percent and 3.6 percent); nasopharyngitis ; headache ; urinary system disease ; upper respiratory tract an infection ; back pain ; diarrhea ; nausea ; and dyspnea . Bertil Lindmark, Chief Scientific Officer at Almirall. Marco Taglietti, President of Forest Analysis Institute. About AUGMENT/COPD Stage III Study AUGMENT was a 24-week randomized double-blind trial analyzing the 400/12mcg and 400/6mcg fixed dose combos of aclidinium bromide/formoterol fumarate compared with aclidinium bromide 400mcg, formoterol fumarate 12mcg and placebo administered BID through the Pressair inhaler in 1,692 sufferers with moderate to serious COPD in the USA, Australia and New Zealand.e., showing superiority in FEV1 at week 24 of the fixed dose mixture over aclidinium at 1 hour post-dose and over formoterol at morning pre-dose trough): 1.The new research which is published in The Lancet this week also notes potential legal implications for people who believe themselves to be noninfectious but go on to have unsafe sex and infect their partner. Dr Wilson is the first writer on a paper that predicts that HIV transmission over a ten-12 months period would be four instances higher in serodiscordant couples who abandon condom make use of than if condoms have been used. The research is founded on mathematical modeling in a population of 10,000 couples where one is normally HIV positive and the various other is HIV harmful.